All the Drug Class Drugs
Monoclonal Antibody. Brentuximab Vedotin 50 mg. VIAL (Pwdr. for conc. for solution for IV infus.): 1 x 50 mg. The recom. dose is 1.8 mg/kg administ. as an IV infus. over 30 min. every 3 wks. If the pt. weight >100 kg, the dose calcul. should use 100 kg. Tmt. should be cont. until dis. progress. or unaccep.tox. Pts. who achieve stab. dis. or better should receive a minim. of 8 cycles and up to a max. of 16 cycles (approx. 1 year). Pts. with CTCL should receive up to 16 cycles. Dose should be individ. ajust in pts. with new or worsen. periph. sens./motor neuropath., neutpropen. The recomm. start. dose in pts with sev. renal impair or hep. impair. is 1.2 mg/ kg admin. as IV infus. over 30 min. every 3 wks. See lit.
Tmt. of adult pts. with relapsed or refractory CD30+ Hodgkin lymphoma (HL). Follow. autologous stem cell transplant (ASCT) or follow. at least two prior therapies when ASCT or multi-agent chemother. is not a tmt. option. Tmt. of adult pts. with CD30+ HL at incr. risk of relapse or progress. follow. ASCT. Tmt. of adult pts. with relapsed or refract. system. anaplastic large cell lymphoma (sALCL). Tmt. of adult pts. with CD30+ cutaneous T-cell lymphoma (CTCL) after at least 1 prior syst. ther.
C/I: Hypersens., comb. use with Bleomycin.
Monoclonal Antibody, VEGF Inhibitor. Bevacizumab 25 mg/ml. VIALS: 1 x 100 mg/4 ml; 1 x 400
Dosage adjust. individ. for each pt.
accord to the med. cond. accord. to
Tmt. metastat. Carcinoma of the colon or
rectum, to be used in combinat. With
Firstline tmt. metastat. Breast cancer, in
comb. with Paclitaxel. tmt.
NSCLC other than predom. squamous cell
histology, in add. to platinum-based
chemother. tmt. advanc./metastat. Renal
cell cancer, in comb. with interferon alfa-
2a. Firstline tmt. advanc./metastat. Renal
cell cancer, in comb. with interferon alfa-
2a. As single agent tmt. glioblastom. In
pts. with progress. dis. foll. prior ther.
Front-line tmt. in comb. with paclitaxel.
and carboplatin advanc. (FIGO III B, III
C,IV) epithelial ovar., fallop. tube, or
primary peritoneal canc. in pts at high risk
for recurrence (resid. dis. aft.debulk.). in
comb. with carboplatin and gemcitabine
tmt of adult pts. with first recur.of
platinum-sensit. epithelial ovar., fallopian
tube or prim. peritoneal cancer who have
not received prior therapy with
Bevacizumab or other VEGF inhibit. or
VEGF receptor–targeted agents.
C/I: Hypersens. active substance/
excips./ chinese hamster ovary/ other recombinant human or humanized
Monoclonal Antibody. Inotuzumab Ozogamicin 1 mg/vial. VIAL(pwdr. for concentrat. for sol. for infus.): 1. The drug should be admin. in 3- to 4-wk. cycles.
For pts. proceed. to haematopoietic stem cell transplant (HSCT), the recommend. duration of tmt. is 2 cycles. A 3rd cycle may be consid. for those pts. who do not achieve a complete remis. (CR) or complete remiss. with incomp. haematolog. recovery (CRi) and min. residual dis. (MRD) negative. after 2 cycles. For pts. not proceed. to HSCT, addit. cycles of tmt, up to a max. of 6 cycles, may be admin. Pts. who do not achieve a CR/CRi within 3 cycles should discont. tmt.
For the 1st t cycle, the recomm. total dose: Inotuzumab ozogamicin for all pts. is 1.8 mg/m² per cycle, given as 3 divid. doses on Days 1 (0.8 mg/m²), 8 (0.5 mg/m²), and 15 (0.5 mg/m²). Cycle 1 is 3 wks. in durat., but may be extend. to 4 wks. if the pt. achieves a CR or CRi, and/or to allow recovery from toxicity.
For subseq. cycles, the recomm. total dose: Inotuzumab ozogamicin is 1.5 mg/m² per cycle given as 3 divided doses on Days 1 (0.5 mg/m²), 8 (0.5 mg/m²), and 15 (0.5 mg/m²) for pts. who achieve a CR/CRi or 1.8 mg/m² per cycle given as 3 divided doses on Days 1 (0.8 mg/m²), 8 (0.5 mg/m²), and 15 (0.5 mg/m²) for pts. who do not achieve a CR/CRi. Subseq. cycles are 4 wks. in durat.
Dose modific. may be required based on individ. safety and tolerab. Manag. of some ADR's. See lit.
Indic. as monother. for the tmt. of adult. with relapsed or refract. CD22-posit. B cell precurs. acute lymphoblast. leuk. (ALL). Adult pts. with Philadelphia chromosome posit. (Ph+) relapsed or refract. B cell precursor ALL should have failed tmt. with at least 1 tyrosine kinase inhib.(TKI).
C/I: Hypersens. Pts. who have experienc. prior confirm. severe or ongoing venoocclusive hep. dis. /sinusoidal obstruct. syndr. (VOD/SOS). Pts. with serious ongoing hep. dis.e.g., cirrhosis, nodular regenerative hyperplasia, active hepatitis).
Monoclonal Antibody. Blinatumomab 12.5 mcg/ml. VIAL(concent. for sol. for infus.+ stabilizer sol. for infus.): 1×35mcg. Recommended dose (for adult patients at least 45 kg in weight): 1st Cycle Start. dose Days 1 – 7: 9 mcg/d via cont. infus. Subseq. dose Days 8 – 28: 28 mcg/d via cont. infus. 2 week-tmt. free interval (Days 29 – 42). 2nd cycle & subseq. cycles (Days 1 – 28): 28 mcg/d via cont. infus. See lit.
Tmt. of adult pt. with Philadelphia chromosome-negat. relapsed/ refract.B‑cell precursor ALL. Limitations of use: After fail. of two previous tmts. and with no CNS involvem.
C/I: Hyperses, lact.
Monoclonal Antibody. Reslizumab 10 mg/ml. VIAL(Concent. for sol. for infus.): 1×10ml, 100ml. IV infus. only. Do not admin. as an IV push or bolus. The recomm. regimen is 3 mg/kg once every 4 wks. admin. by IV infus. over 20-50 min. Discont. the infus. immed. if the pt. experience. a sev. syst. react., including anaphylaxis.
Indic. for the add-on mainten. tmt. of pts. with sev. asthma aged 18 yrs. and older with an eosinophilic phenotype.
Monoclonal Antibody. Daratumumab 20 mg/ml. Vial(Concentr. for sol. for IV infus.): 1 × 5, 20ml.
16 mg/kg body weight admin. as an IV infuse. accord. to the follow. dosing schedule: Wkly.: 1st – 8th week. Every 2 wks.: 9th -24th week. Every 4 wks.: 25th week onwards until dis. progres.
As monother. is indic. for the tmt. of adult pts. with relapsed and refract. multiple myeloma, whose prior ther. includ. a proteasome inhib. and an immunomodulat. agent and who have demonstrated dis.progres. on the last ther.